1/8
09:00 am
kzia
Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End
Low
Report
Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End
12/22
08:10 am
kzia
Kazia Therapeutics Regains Full Nasdaq Listing Compliance [Yahoo! Finance]
Medium
Report
Kazia Therapeutics Regains Full Nasdaq Listing Compliance [Yahoo! Finance]
12/22
08:00 am
kzia
Kazia Therapeutics Regains Full Nasdaq Listing Compliance
Medium
Report
Kazia Therapeutics Regains Full Nasdaq Listing Compliance
12/12
08:06 am
kzia
Novogen (NASDAQ:KZIA) had its price target raised by analysts at HC Wainwright from $13.00 to $18.00. They now have a "buy" rating on the stock.
High
Report
Novogen (NASDAQ:KZIA) had its price target raised by analysts at HC Wainwright from $13.00 to $18.00. They now have a "buy" rating on the stock.
12/10
08:00 am
kzia
Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+
High
Report
Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+
12/2
09:00 am
kzia
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities
Medium
Report
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities
11/18
04:56 pm
kzia
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy [Yahoo! Finance]
High
Report
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy [Yahoo! Finance]
11/18
04:15 pm
kzia
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy
High
Report
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy
10/30
05:31 pm
kzia
Atypical Teratoid/Rhabdoid Tumor Treatment Market Shows Promising CAGR During the Forecast Period (2025-2034) with Growing Clinical Trials and R&D Initiatives | DelveInsight
Medium
Report
Atypical Teratoid/Rhabdoid Tumor Treatment Market Shows Promising CAGR During the Forecast Period (2025-2034) with Growing Clinical Trials and R&D Initiatives | DelveInsight
10/30
05:31 pm
kzia
Atypical Teratoid/Rhabdoid Tumor Treatment Market Shows Promising CAGR During the Forecast Period (2025-2034) with Growing Clinical Trials and R&D Initiatives | DelveInsight
Medium
Report
Atypical Teratoid/Rhabdoid Tumor Treatment Market Shows Promising CAGR During the Forecast Period (2025-2034) with Growing Clinical Trials and R&D Initiatives | DelveInsight
10/27
07:15 am
kzia
Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner
Low
Report
Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner